NovoCure Limited

US$13.28As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:NVCRHealthcare
Country USA
PE (Fwd) •••
TSR 10Y CAGR 8.16%
Div yield —
ROE (35.18%)
Medical Devices
Beta (5Y) 1.08
PE TTM —
TSR TTM 3.67%
Mkt cap US$1.553B
ROIC (95.37%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$16
23.31%
(4.10%)
Hold 7|9|9|9|10
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.23
0.24
0.25
0.27
7.31%
17.98%
19.59%
25.24%
Revenue$M
74.52
78.29
78.57
81.24
11.45%
10.55%
12.19%
9.87%
Peers (US$1.553B)
Cap (US$)
PE
2.603B
29.78x
1.673B
91.41x
954.4M
111.0x
Capital
TTM
5Y
10Y
Leveragex
1.413
0.222
0.184
EBIT/Intx
4.559
0.373
0.366
Own earn%
64.62
(85.98)
(65.98)
Sh yield%
37.09
36.81
38.02
Owners
Insiders/Inst%
7.73
42.57
Short interest%
0.99
SBC / revenue%
5.88
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
25
Op margin range%
25–34
$1 testx
—
Incr. ROIC%
4